# Erythropoietin Effect on Complement Activation in Chronic Kidney Disease

## TL;DR

This study shows that erythropoietin therapy in chronic kidney disease patients increases complement activation and may worsen inflammation.

## Contribution

The study reveals a novel link between erythropoietin treatment and complement system dysregulation in chronic kidney disease.

## Key findings

- Erythropoietin therapy increased serum C3a and C5a levels in CKD patients.
- EPO treatment reduced CD55 and CD59 levels in T and B cells.
- Complement activation may contribute to tissue injury in CKD patients on EPO.

## Abstract

The complement system is an important part of innate immunity. Despite its known protective role, the complement system may contribute to increased inflammation and tissue injury in cases where its balanced activation is disrupted. The kidneys have been shown to be largely affected by complement dysregulation. The aim of the present study was to investigate the effect of erythropoietin administration, on the complement system, in chronic kidney disease patients. The study involved 20 patients with CKD who received erythropoietin and measurements of levels of complement factors C3a and C5a and complement regulatory proteins (CregPs) CD55, CD46, and CD59. An increase in serum C3a and C5a levels was observed in response to EPO therapy. The increase in C3a was statistically significant (p < 0.05) and concurrent with a statistically significant decrease in CD55 in CD4+ T cells (p < 0.05) and B cells (p < 0.05) and CD59 levels in CD4+ and CD8+ T cells (p < 0.05) at completion of EPO therapy compared with healthy controls. The above observations demonstrate that EPO induces complement activation in patients undergoing EPO therapy with a simultaneous restriction of CRegPs expression, thus possibly allowing the uncontrolled complement activation, which may contribute to tissue injury and disease progression.